| Date | Name | Title | Filing | Type | Shares Traded | Price Range | Total Held |
|---|---|---|---|---|---|---|---|
| Jul 14, 2020 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 15,323 | -- | 15,323 | |
| Jul 14, 2020 | EVP and CFO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 15,121 | -- | 60,620 | |
| Jul 14, 2020 | EVP and CFO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 30,242 | -- | 30,242 | |
| Jul 14, 2020 | EVP and CFO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 44,510 | -- | 44,510 | |
| May 23, 2020 | SVP/GM, Vascular Access | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 826 | $11.21 | 18,102 | |
| Apr 04, 2020 | Director, President and CEO | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 4,245 | $10.23 | 256,173 | |
| Feb 12, 2020 | SVP and GM of Oncology | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 490 | $12.99 | 15,416 | |
| Feb 03, 2020 | EVP, General Counsel and CFO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 5,376 | -- | 45,499 | |
| Feb 03, 2020 | EVP, General Counsel and CFO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 18,204 | -- | 18,204 | |
| Jan 17, 2020 | SVP and GM of Oncology | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 490 | $15.48 | 15,906 |
For recent transactions, including derivative transactions, see our Section 16 SEC filings page.